NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
Clinical Trials
12 trialsNCT06598371 2026-02-11
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06066424 2025-10-14
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05881525 2025-07-16
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase 1 Recruiting
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT07010523 2025-06-08
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University
Phase NA Recruiting
NCT06773091 2025-02-11
NKSOLID
Shanghai NK Cell Technology Co., LTD
Phase 1 Recruiting
NCT05693844 2024-05-10
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06394622 2024-05-01
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Fudan University
Phase 1 Recruiting
NCT06101082 2024-03-06
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
China Medical University, China
Phase 1 Recruiting
NCT05681650 2023-12-12
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting